AbbVie’s JUVMO (tavapadon) targets dopamine differently from older drugs and is expected in US pharmacies this month, the company says.
Link as first comment.
@longevitytech.bsky.social
Explore
@longevitytech.bsky.social
@newsen.bsky.social
@longevitytech.bsky.socialAbbVie’s JUVMO (tavapadon) targets dopamine differently from older drugs and is expected in US pharmacies this month, the company says.
Link as first comment.
@newsen.bsky.social